The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Early Identification of Refractory Epilepsy
Open accessAbstract
BACKGROUND: More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown. We studied the response to antiepileptic drugs in patients with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures. METHODS: We prospectively studied 525 patients (age, 9 to 93 years) who were given a diagnosis, treated, and followed up at a single center between 1984 and 1997. Epilepsy was classified as idiopathic (with a presumed genetic basis), symptomatic (resulting from a structural abnormality), or cryptogenic (resulting from an unknown underlying cause). Patients were considered to be seizure-free if they had not had any seizures for at least one year. RESULTS: Among the 525 patients, 333 (63 percent) remained seizure-free during antiepileptic-drug treatment or after treatment was stopped. The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001). The seizure-free rate was similar in patients who were treated with a single established drug (67 percent) and patients who were treated with a single new drug (69 percent). Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug. In 12 patients (3 percent) epilepsy was controlled by treatment with two drugs. Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent). CONCLUSIONS: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the remaining 30% have drug-resistant epilepsy requiring consideration of surgical intervention, ketogenic dietary therapy, vagus nerve stimulation, or other neuromodulatory approaches6,7”
In the citing paper
“While approximately 70% of patients can achieve seizure freedom with appropriate antiepileptic drug (AED) therapy”
Citations
Cites
Guidelines for Epidemiologic Studies on Epilepsy
(1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb00433.x · Cited by 1,360
Is the underlying cause of epilepsy a major prognostic factor for recurrence?
Semah, F., Picot, M., Adam, C., Broglin, D., Arzimanoglou, A. A., Bazin, B., Cavalcanti, D., & Baulac, M. (1998) · Neurology · doi:10.1212/wnl.51.5.1256 · Cited by 1,105
Engel, J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603073341008 · Cited by 880
Long-Term Prognosis of Seizures with Onset in Childhood
Sillanpää, M. L., Jalava, M., Kaleva, O., & Shinnar, S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806113382402 · Cited by 725
Remission of Seizures and Relapse in Patients with Epilepsy
Annegers, J. F., Hauser, W. A., & Elveback, L. R. (1979) · Epilepsia · doi:10.1111/j.1528-1157.1979.tb04857.x · Cited by 621
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. W. C. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 614
Self-citationMDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy
Tishler, D. M., Weinberg, K. I., Hinton, D. R., Barbaro, N. M., Annett, G., & Raffel, C. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01657.x · Cited by 529
Multidrug resistance: molecular mechanisms and clinical relevance
Ling, V. W. T. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 525
Brodie, M. J., Overstall, P. W., & Giorgi, L. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(99)00039-x · Cited by 462
Self-citation
Research works printed but not linked: 2
- Dreifuss FE. Classification of epileptic seizures. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Vol. 1. Philadelphia: Lippincott-Raven, 1998:517-24.
- Wolf P. International classification of the epilepsies. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Vol. 1. Philadelphia: Lippincott-Raven, 1998:773-7.
Cited by
Sorted by citations
Items 1,001–1,005 of 1,005
Management of Drug-Resistant Epilepsy
Nair, D. R. (2016) · Continuum · doi:10.1212/con.0000000000000297 · Cited by 68
Kreilkamp, B. A. K., Lisanti, L., Glenn, G. R., Wieshmann, U. C., Das, K., Marson, A. G., & Keller, S. S. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102024 · Cited by 27
Psychological treatments for people with epilepsy
Michaelis, R., Tang, V., Nevitt, S. J., Wagner, J. L., Modi, A. C., LaFrance Jr, W. C., Goldstein, L. H., Gandy, M., Bresnahan, R., Valente, K., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012081.pub3 · Cited by 37
Chakravorti, S., Jermakowicz, W. J., Wu, C., Li, R., Wirz Gonzalez, R., Dawant, B. M., & D'Haese, P.-F. (2019) · Medical Imaging 2019: Image-Guided Procedures, Robotic Interventions, and Modeling · doi:10.1117/12.2512587 · Cited by 3
Zhang, Y.-J., Guo, Y.-Y., & Wang, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-52532-5 · Cited by 3
Metadata
- Authors
- Kwan, P., & Brodie, M. J.
- Affiliations
- Western Infirmary (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-02-03
- Volume
- 342
- Issue
- 5
- Pages
- 314-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974809694
- Cited by
- 5,204
- References
- 39
- Citations by year
- 2026: 225 · 2025: 241 · 2024: 259 · 2023: 275 · 2022: 269 · 2021: 328 · 2020: 348 · 2019: 253 · 2018: 270 · 2017: 228 · 2016: 249 · 2015: 230 · 2014: 205 · 2013: 233 · 2012: 248
- FWCI
- 55.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- drug-resistant epilepsy, antiepileptic drugs, seizure control, newly diagnosed epilepsy, idiopathic epilepsy, symptomatic epilepsy, cryptogenic epilepsy, seizure frequency, predictors of treatment failure, adverse drug reactions, polypharmacy
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anticonvulsants, Child, Epilepsy, Female, Humans, Male, Middle Aged, Prospective Studies, Remission Induction, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review